Skip to content

Sweetgoals for Type 1 Diabetes

Thinking Outside the Clinic: A Digital Health Approach for Young Adults With Type 1 Diabetes

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04646473
Enrollment
300
Registered
2020-11-30
Start date
2021-07-25
Completion date
2025-04-30
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Brief summary

The study will test an app and web-delivered intervention designed to improve glycemic control (HbA1c) among young adults with Type 1 diabetes. All participants will receive the "core" digital intervention, the SweetGoals app, focused on self-monitoring and goal setting. Efficacy of two independent intervention components (incentives for adherence and web health coaching) will be tested

Detailed description

ASSIGNMENT OF PARTICIPANTS: Interested participants will download the SweetGoals app. Once all screening procedures are complete, including A1c verification via the mail in test kit, research staff will schedule a web video meeting to (1) randomize participants and inform them of their intervention condition assignment; (2)assist participants in setting up their Glooko account and uploading their devices and orient them to the Glooko data visualization hub; and (3) download the Glooko mobile app, which may be used by all participants and into which participants without a Glooko compatible pump will enter carb counts. INTERVENTION DELIVERY: All participants will receive the core intervention, the SweetGoals app. Those assigned to Incentives will receive the app plus incentives for meeting adherence goals. Those assigned to Coaching will receive web health coaching to increase motivation and skill in self-management as described below. DIABETES CARE FOR ALL PARTICIPANTS: Participants in all conditions will receive ongoing treatment for type 1 diabetes from their current medical provider. Report of a visit within the past 6 months is a study inclusion criterion. Study staff will not provide medical care or intervention. All participants will receive information about recommendations for medical care related to diabetes (e.g., quarterly visits and A1c assessment, consistent with Standards of Medical Care in Diabetes). Informational links will be provided within SweetGoals for various online resources addressing T1D educational topics. CORE INTERVENTION FOR ALL PARTICIPANTS: SWEETGOALS APP All participants will receive the SweetGoals app, an automated intervention that sets weekly self-management goals and provides weekly feedback. The SweetGoals app will be implemented and delivered using the MobileCoach app platform, which runs on both Android and iOS systems. The SweetGoals app sends weekly reminders to upload devices, retrieves device data via the Glooko API, applies decision rules to evaluate daily and weekly goals, and sends weekly feedback messages about goal adherence and encouragement about adherence in the upcoming week. Diabetes Self-Management Goals. Glooko stores multiple variables that are used to evaluate the glucose monitoring and mealtime goals. Across both glucose monitoring and mealtime target behaviors, we use a similar structure to the goals to promote ease of remembering the goals and communication with participants. Specifically, regardless of the devices used or the target (glucose monitoring or mealtime behaviors) there is a daily adherence goal, and there is a weekly goal of meeting the daily goal on \>5 days each week. These weekly goals were selected to promote high consistency in mealtime glucose monitoring and carb counting. Each week, participants will be asked to set personal goals for the next week for the number of days they think they can meet each daily goal. Each week they will receive a message stating the number of days on which they met each goal, how that compared to their personal goal, and whether they met the ultimate weekly goal (met daily goal \>5 days per week). Glucose monitoring goals. Each participant will receive a device-specific (glucometer vs. CGM) daily goal based on the device they use to monitoring their glucose levels, and the ultimate weekly goal for all participants is to meet the daily goal on at least 5 days per week. For participants who use a glucometer only, the daily self-monitoring of blood glucose (SMBG) goal is \>5 checks, each \>2 hours from another check. For participants who use CGM, the CGM wear time goal is 80% of expected values each day. Expected values per day are based on the device-specific check frequency (e.g., every 5 mins for Dexcom G6). We selected this cutoff to reflect clinically necessary glucose monitoring frequency, but also allow for legitimate disconnect time (sports, leisure activities) and sensor changes. Mealtime goals. Each participant will receive daily goals specific to their insulin delivery method (pump vs. MDI). Participants will be asked to check their glucose before they eat (if they use a glucometer only, not CGM). Participants who use a Glooko compatible pump will only need to use their pump to document the mealtime goals. If they use a pump+glucometer combination that requires manual entry of the glucose value into the pump, they must complete the glucose check and that manual entry no longer than 30 minutes before the carb entry to receive credit for meeting the mealtime goal. If they use a pump+CGM or other meter that transfers the glucose value to the pump without manual entry, no manual entry is necessary. If they use MDI (no insulin pump), they will use the Food event screen to enter their carb counts in the Glooko smartphone app. When each participant's Glooko data are retrieved, our algorithm evaluates whether or not there is a valid glucose value within 30 minutes prior to each carb entry. The daily mealtime target is 3 paired glucose level/carb count values. INCENTIVE COMPONENT In addition to using the SweetGoals app, participants assigned to Incentives will also receive incentives for meeting goals. Incentives to improve adherence to glucose monitoring and mealtime behaviors that support appropriate insulin bolusing are paid weekly from weeks 1-11, then fade in frequency from weeks 12-25, a procedure used to promote long lasting improvements in adherence and A1c. In the fading phase, incentives are paid at increasing time intervals (i.e., 2,3,4 then 5-week delays; paid at weeks 13, 16, 20, 25). For meeting daily and weekly goals, participants can earn the following incentives: (1) $1 for each day meeting glucose monitoring goal. (maximum=$7 per week); (2) $5 per week bonus for meeting the glucose monitoring goal 6 or 7 days to promote consistent weekly glucose monitoring. (maximum=$5 per week) (3) $1 for every day with \>3 properly timed glucose value/carb entry pairs (maximum=$7 per week); (4) $5 per week bonus for meeting the mealtime goal 6 or 7 days to promote consistent weekly glucose checking and carb counting at mealtime. (maximum=$5 per week). Total earnings possible each week are $24 (\ $3.50 per day). The maximum earnings for all goals are $600 across 25 weeks. Research staff will load earned incentives on reloadable prepaid MasterCards. WEB HEALTH COACHING COMPONENT: Participants assigned to coaching will also receive 15 Web Health Coaching sessions by a bachelors-level health coach. These coaching sessions are designed to promote effective self-management of diabetes. Coaching sessions are held weekly from weeks 1-11, then fade over the second half of the intervention with 4 sessions held during weeks 12-25 (weeks 13, 16, 20, and 25). Sessions 1-7 are 30 minutes each, as new material is introduced and practiced. Sessions 8-15 are 15 minutes each, as problem solving skills are practiced and applied to new challenges identified by participants. Coaching will be completed using Zoom, an online HIPAA compliant web conference system.

Interventions

BEHAVIORALCoaching

Web health coaching

BEHAVIORALIncentives

Financial incentives for meeting goals

BEHAVIORALSweetgoals app

App provides weekly feedback about behavioral goals

Sponsors

Trustees of Dartmouth College
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Optimization study. Main effects of each intervention condition are the primary aims.

Eligibility

Sex/Gender
ALL
Age
19 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

* Have a diagnosis of T1D for \>18 months * Have A1c ≥7.5% * Report a visit with physician managing type 1 diabetes (T1D) within the previous 6 months * Participants must use a glucometer or continuous glucose monitor compatible with Glooko.

Exclusion criteria

* Pregnancy or breast feeding * Severe medical illness that would preclude participation (e.g., cystic fibrosis, developmental disability, severe cognitive impairment) * Psychiatric illness that would preclude participation * Diabetes diagnoses other than T1D (Type 2 Diabetes, Maturity Onset Diabetes of the Young/MODY) * Use of any medications known to impact glycemic control (oral or injectable corticosteroids, beta-blockers, antipsychotic medications such as risperidone). * A history of known hemoglobinopathy, anemia, or transfusion (which could alter the validity of HbA1c measurement) * Already being engaged in a psychological intervention targeting diabetes adherence.

Design outcomes

Primary

MeasureTime frameDescription
Percent Glycated Hemoglobin/6 MonthsFrom Baseline to Month 12Estimated mean change (slope) in percent glycated hemoglobin per each 6 month interval from Baseline to Month 12 were obtained from a growth curve analysis using maximum likelihood estimation to account for missing data. All randomized participants were utilized in the model (ITT analysis).
Change in Hba1c at 12 Months, Main Effects of Each Intervention Component12 months, controlling for baselineEstimated mean change from Baseline to Month 12 were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months vs. baseline associated with the On level of the intervention condition relative to the Off level of the intervention condition.

Secondary

MeasureTime frameDescription
Change in Percent Glycated Hemoglobin Per Day of Glucose Checking Goal AchievementAt 12 months, controlling for baselineEstimated mean change from baseline to Month 12 was obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months from baseline associated with each additional day of glucose checking goal achievement during the 6-month intervention period.
Change in Percent Glycated Hemoglobin Per Day of Mealtime Goal AchievementAt 12 months, controlling for baselineEstimated mean change from baseline to Month 12 was obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months from baseline associated with each additional day of mealtime goal achievement during the 6-month intervention period.
Days Per Week Meeting Glucose Checking Goal During Intervention Period, Main Effects of Each Intervention ComponentBaseline to 6 monthsEstimated mean days per week meeting checking goal were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the difference in the mean days per week the checking goal was met associated with the On level of each intervention condition relative to the Off level of the intervention condition.
Days Per Week Meeting Mealtime Goal During Intervention Period, Main Effects of Each Intervention ComponentBaseline to 6 monthsEstimated mean days per week meeting mealtime goal were obtained from a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the difference in the mean days per week the goal was met associated with the On level of each intervention condition relative to the Off level of the intervention condition.
Change in Percent Glycated Hemoglobin Due to Each Intervention Mediated by Days Met Glucose Checking GoalBaseline to 12 monthsEstimated mean change from Baseline to12 months were obtained from a a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months resulting from the impact of the On level of each intervention condition relative to the Off level of the intervention condition as mediated by the mean days per week the glucose checking goal was met.
Change in Percent Glycated Hemoglobin Due to Each Intervention Mediated by Days Met Mealtime GoalBaseline to 12 monthsEstimated mean change from Baseline to12 months were obtained from a a maximum likelihood structural path model to account for missing data. All randomized participants were utilized in the model (ITT analysis). This outcome measure is reported as the change in HbA1c at 12 months resulting from the impact of the On level of each intervention condition relative to the Off level of the intervention condition as mediated by the mean days per week the mealtime goal was met.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCatherine Stanger, Ph.D.

Trustees of Dartmouth College

Participant flow

Recruitment details

Recruitment via social media. Enrolled from July 25, 2021 to 03/25/2024.

Baseline characteristics

Characteristic
Age, Continuous23.40 years
STANDARD_DEVIATION 2.97
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
68 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
HbA1c8.92 percent
STANDARD_DEVIATION 1.08
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
8 Participants
Race (NIH/OMB)
Black or African American
30 Participants
Race (NIH/OMB)
More than one race
17 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants
Race (NIH/OMB)
White
239 Participants
Sex/Gender, Customized
Female
50 Participants
Sex/Gender, Customized
Male
22 Participants
Sex/Gender, Customized
Other
2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 750 / 750 / 750 / 75
other
Total, other adverse events
0 / 750 / 750 / 750 / 75
serious
Total, serious adverse events
3 / 752 / 751 / 752 / 75

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026